These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 22789854)
1. On mechanism of allosteric modulation of NMDA receptor via amino-terminal domains. Karlov DS; Radchenko EV; Zefirov AN; Palyulin VA; Pentkovski VM; Zefirov NS Biochem Biophys Res Commun; 2012 Aug; 424(4):687-90. PubMed ID: 22789854 [TBL] [Abstract][Full Text] [Related]
2. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold. Ritter N; Korff M; Markus A; Schepmann D; Seebohm G; Schreiber JA; Wünsch B Cell Physiol Biochem; 2021 Mar; 55(S3):1-13. PubMed ID: 33656308 [TBL] [Abstract][Full Text] [Related]
3. The function of the amino terminal domain in NMDA receptor modulation. Huggins DJ; Grant GH J Mol Graph Model; 2005 Jan; 23(4):381-8. PubMed ID: 15670959 [TBL] [Abstract][Full Text] [Related]
4. Functional evidence for a twisted conformation of the NMDA receptor GluN2A subunit N-terminal domain. Stroebel D; Carvalho S; Paoletti P Neuropharmacology; 2011 Jan; 60(1):151-8. PubMed ID: 20621105 [TBL] [Abstract][Full Text] [Related]
5. Chimeric Glutamate Receptor Subunits Reveal the Transmembrane Domain Is Sufficient for NMDA Receptor Pore Properties but Some Positive Allosteric Modulators Require Additional Domains. Wilding TJ; Lopez MN; Huettner JE J Neurosci; 2016 Aug; 36(34):8815-25. PubMed ID: 27559165 [TBL] [Abstract][Full Text] [Related]
6. Zinc and ifenprodil allosterically inhibit two separate polyamine-sensitive sites at N-methyl-D-aspartate receptor complex. Berger ML; Rebernik P J Pharmacol Exp Ther; 1999 Jun; 289(3):1584-91. PubMed ID: 10336556 [TBL] [Abstract][Full Text] [Related]
7. Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-D-aspartate receptors. Kloda A; Clements JD; Lewis RJ; Adams DJ Mol Pharmacol; 2004 Jun; 65(6):1386-96. PubMed ID: 15155832 [TBL] [Abstract][Full Text] [Related]
8. A conserved structural mechanism of NMDA receptor inhibition: A comparison of ifenprodil and zinc. Sirrieh RE; MacLean DM; Jayaraman V J Gen Physiol; 2015 Aug; 146(2):173-81. PubMed ID: 26170175 [TBL] [Abstract][Full Text] [Related]
9. Homology modeling of NR2B modulatory domain of NMDA receptor and analysis of ifenprodil binding. Marinelli L; Cosconati S; Steinbrecher T; Limongelli V; Bertamino A; Novellino E; Case DA ChemMedChem; 2007 Oct; 2(10):1498-510. PubMed ID: 17849398 [TBL] [Abstract][Full Text] [Related]
10. Allosteric interaction between the amino terminal domain and the ligand binding domain of NR2A. Zheng F; Erreger K; Low CM; Banke T; Lee CJ; Conn PJ; Traynelis SF Nat Neurosci; 2001 Sep; 4(9):894-901. PubMed ID: 11528420 [TBL] [Abstract][Full Text] [Related]
11. Deletion of the C-terminal domain of the NR2B subunit alters channel properties and synaptic targeting of N-methyl-D-aspartate receptors in nascent neocortical synapses. Mohrmann R; Köhr G; Hatt H; Sprengel R; Gottmann K J Neurosci Res; 2002 May; 68(3):265-75. PubMed ID: 12111856 [TBL] [Abstract][Full Text] [Related]
12. The NMDA receptor complex: a long and winding road to therapeutics. Wood PL IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895 [TBL] [Abstract][Full Text] [Related]
13. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Karakas E; Simorowski N; Furukawa H Nature; 2011 Jun; 475(7355):249-53. PubMed ID: 21677647 [TBL] [Abstract][Full Text] [Related]
14. Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Bhatt JM; Prakash A; Suryavanshi PS; Dravid SM Mol Pharmacol; 2013 Jan; 83(1):9-21. PubMed ID: 23007555 [TBL] [Abstract][Full Text] [Related]
15. The NR1 M3 domain mediates allosteric coupling in the N-methyl-D-aspartate receptor. Blanke ML; VanDongen AM Mol Pharmacol; 2008 Aug; 74(2):454-65. PubMed ID: 18483226 [TBL] [Abstract][Full Text] [Related]
16. Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. Malherbe P; Mutel V; Broger C; Perin-Dureau F; Kemp JA; Neyton J; Paoletti P; Kew JN J Pharmacol Exp Ther; 2003 Dec; 307(3):897-905. PubMed ID: 14534359 [TBL] [Abstract][Full Text] [Related]
17. A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists. Stroebel D; Buhl DL; Knafels JD; Chanda PK; Green M; Sciabola S; Mony L; Paoletti P; Pandit J Mol Pharmacol; 2016 May; 89(5):541-51. PubMed ID: 26912815 [TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of ligand discrimination in the glutamate-binding pocket of the NMDA receptor. Laube B; Schemm R; Betz H Neuropharmacology; 2004 Dec; 47(7):994-1007. PubMed ID: 15555634 [TBL] [Abstract][Full Text] [Related]
19. Single amino acid residue in the M4 domain of GluN1 subunit regulates the surface delivery of NMDA receptors. Kaniakova M; Lichnerova K; Vyklicky L; Horak M J Neurochem; 2012 Nov; 123(3):385-95. PubMed ID: 22937865 [TBL] [Abstract][Full Text] [Related]
20. A novel family of negative and positive allosteric modulators of NMDA receptors. Costa BM; Irvine MW; Fang G; Eaves RJ; Mayo-Martin MB; Skifter DA; Jane DE; Monaghan DT J Pharmacol Exp Ther; 2010 Dec; 335(3):614-21. PubMed ID: 20858708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]